SCHEMBL461006

SCHEMBL461006

Cc1nc2cc(-c3cccc(Cl)c3)nn2c(CC(C)C)c1C(O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.45
DPP8 Q6V1X1 2/20 0.45
DPP9 Q86TI2 2/20 0.45
NPSR1 Q6W5P4 2/20 0.43
KMT2A Q03164 1/20 0.43
ABCB1 P08183 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL463148 0.90 POLB (0.44) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL463149 0.90 POLB (0.44) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL12078786 0.86 DPP4 (0.47) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL462321 0.86 NR1I2 (0.49) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL462975 0.86 NR1I2 (0.49) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL461477 0.85 DPP4 (0.45) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL12079176 0.84 DPP4 (0.50) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL461241 0.81 POLB (0.42) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL461242 0.81 POLB (0.42) DPP4DPP8DPP9NPSR1KMT2A
SCHEMBL458537 0.80 DPP4 (0.46) DPP4DPP8DPP9NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
EP-2614064-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS DPP4 3849/4885DPP8 3207/4885DPP9 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.